HONLIV HEALTH (09906) announced its interim results for 2025, reporting revenue of 347 million yuan (RMB), representing a 16.5% year-over-year decline. The company recorded a loss attributable to shareholders of 673,000 yuan, compared to a profit attributable to shareholders of 20.042 million yuan in the corresponding period last year, marking a shift from profit to loss.